Denali Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Denali Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||||||||||||||||||
| research and development | 102,696,000 | 116,227,000 | 99,787,000 | 98,238,000 | 91,399,000 | 107,016,000 | 107,803,000 | 89,737,000 | 97,520,000 | 128,816,000 | 92,111,000 | 87,786,000 | 92,737,000 | 86,098,000 | 67,876,000 | 71,559,000 | 65,711,000 | 60,207,000 | 54,743,000 | 53,704,000 | 53,152,000 | 51,016,000 | 51,551,000 | 52,544,000 | 51,884,000 | 37,403,000 | 39,909,000 | 30,321,000 | 52,134,000 | 20,819,000 |
| general and administrative | 32,267,000 | 29,353,000 | 30,059,000 | 24,949,000 | 25,194,000 | 25,236,000 | 24,769,000 | 25,325,000 | 26,120,000 | 27,140,000 | 23,516,000 | 23,259,000 | 21,159,000 | 22,541,000 | 21,759,000 | 19,319,000 | 19,045,000 | 18,936,000 | 17,994,000 | 15,805,000 | 13,972,000 | 12,555,000 | 10,879,000 | 11,215,000 | 15,076,000 | 9,310,000 | 11,045,000 | 8,838,000 | 6,896,000 | 5,570,000 |
| total operating expenses | 134,963,000 | 145,580,000 | 129,846,000 | 123,187,000 | 116,593,000 | 132,252,000 | 132,572,000 | 115,062,000 | 123,640,000 | 155,956,000 | 115,627,000 | 111,045,000 | 113,896,000 | 108,639,000 | 89,635,000 | 90,878,000 | 84,756,000 | 79,143,000 | 72,737,000 | 69,509,000 | 67,124,000 | 63,571,000 | 62,430,000 | 63,759,000 | 66,960,000 | 46,713,000 | 50,954,000 | 39,159,000 | 59,030,000 | 26,389,000 |
| gain from divestiture of small molecule programs | 14,537,000 | |||||||||||||||||||||||||||||
| income from operations | -134,963,000 | -145,580,000 | -129,846,000 | -123,187,000 | -116,593,000 | -117,715,000 | -132,572,000 | -113,795,000 | 170,483,000 | -120,815,000 | -105,344,000 | -107,486,000 | -61,416,000 | -66,498,000 | -77,121,000 | -85,593,000 | -61,817,000 | -71,220,000 | 244,078,000 | -60,116,000 | -61,277,000 | -59,967,000 | -57,758,000 | -50,155,000 | -62,763,000 | -42,508,000 | 74,722,000 | -37,964,000 | -57,382,000 | -25,748,000 |
| yoy | 15.76% | 23.67% | -2.06% | 8.25% | -168.39% | -2.57% | 25.85% | 5.87% | -377.59% | 81.68% | 36.60% | 25.58% | -0.65% | -6.63% | -131.60% | 42.38% | 0.88% | 18.77% | -522.59% | 19.86% | -2.37% | 41.07% | -177.30% | 32.11% | 9.38% | 65.09% | ||||
| qoq | -7.29% | 12.12% | 5.41% | 5.66% | -0.95% | -11.21% | 16.50% | -166.75% | -241.11% | 14.69% | -1.99% | 75.01% | -7.64% | -13.77% | -9.90% | 38.46% | -13.20% | -129.18% | -506.01% | -1.89% | 2.18% | 3.82% | 15.16% | -20.09% | 47.65% | -156.89% | -296.82% | -33.84% | 122.86% | |
| operating margin % | -8981.45% | 57.96% | -343.80% | -1024.45% | -3020.12% | -117.03% | -157.80% | -616.28% | -1619.55% | -269.48% | -898.90% | 77.04% | -640.01% | -1048.01% | -1663.90% | |||||||||||||||
| interest and other income | 10,844,000 | 12,610,000 | 15,161,000 | 15,995,000 | 17,567,000 | 15,913,000 | 13,129,000 | 14,442,000 | 12,900,000 | 11,034,000 | 6,660,000 | 4,187,000 | 2,649,000 | 1,278,000 | 1,285,000 | 1,005,000 | 1,126,000 | 1,179,000 | 1,630,000 | 1,944,000 | 2,598,000 | 3,069,000 | 3,808,000 | 3,782,000 | 4,113,000 | 3,516,000 | 2,811,000 | 2,593,000 | 2,658,000 | |
| net income | -124,119,000 | -132,970,000 | -114,753,000 | -107,192,000 | -99,026,000 | -101,802,000 | -119,473,000 | -99,353,000 | 183,383,000 | -109,781,000 | -98,678,000 | -103,299,000 | -58,794,000 | -65,220,000 | -75,261,000 | -84,588,000 | -60,691,000 | -70,041,000 | 244,885,000 | -58,228,000 | -58,758,000 | -56,763,000 | -54,025,000 | -46,260,000 | -58,337,000 | -38,992,000 | 77,533,000 | -35,371,000 | -54,724,000 | -23,678,000 |
| yoy | 25.34% | 30.62% | -3.95% | 7.89% | -154.00% | -7.27% | 21.07% | -3.82% | -411.91% | 68.32% | 31.11% | 22.12% | -3.13% | -6.88% | -130.73% | 45.27% | 3.29% | 23.39% | -553.28% | 25.87% | 0.72% | 45.58% | -169.68% | 30.79% | 6.60% | 64.68% | ||||
| qoq | -6.66% | 15.87% | 7.05% | 8.25% | -2.73% | -14.79% | 20.25% | -154.18% | -267.04% | 11.25% | -4.47% | 75.70% | -9.85% | -13.34% | -11.03% | 39.37% | -13.35% | -128.60% | -520.56% | -0.90% | 3.51% | 5.07% | 16.79% | -20.70% | 49.61% | -150.29% | -319.20% | -35.36% | 131.12% | |
| net income margin % | -7841.59% | 62.35% | -312.40% | -959.62% | -2902.47% | -112.03% | -154.77% | -601.41% | -1600.53% | -264.58% | -884.02% | 77.30% | -619.91% | -1004.93% | -1575.00% | |||||||||||||||
| net income per share | -0.72 | -0.78 | -0.68 | -0.63 | -0.59 | -0.68 | -0.87 | -0.72 | 1.34 | -0.8 | -0.463 | -0.84 | -0.48 | -0.53 | -0.443 | -0.69 | -0.5 | -0.58 | -0.413 | -0.54 | -0.56 | -0.55 | -0.57 | -0.48 | -0.61 | -0.41 | 0.85 | -0.38 | -0.59 | -0.26 |
| weighted-average number of shares outstanding, basic and diluted | 171,449,847 | 171,222,030 | 164,473,772 | 169,456,988 | 149,404,188 | 137,370,897 | 137,644,534 | 136,524,528 | 123,473,390 | 123,008,558 | 122,673,935 | 121,742,067 | 121,291,435 | 120,884,665 | 107,490,702 | 105,717,912 | 102,419,718 | 95,608,208 | 95,859,048 | 95,495,497 | 94,984,503 | 92,621,991 | 93,665,231 | 92,899,524 | 89,560,576 | |||||
| comprehensive loss | -125,217 | -132,953,000 | -118,262,000 | -99,004,000 | -103,741,000 | -118,179,000 | -98,563,000 | -105,412,000 | -59,166,750 | -102,878,000 | -61,817,000 | -71,972,000 | -53,899,000 | -84,741,000 | -60,827,000 | -70,028,000 | -43,522,000 | -58,768,000 | -59,042,000 | -56,278,000 | -54,237,000 | -46,577,000 | -57,790,000 | -38,011,000 | 78,300,000 | -35,294,000 | -54,930,000 | -24,597,000 | ||
| other comprehensive loss: | ||||||||||||||||||||||||||||||
| net unrealized loss on marketable securities, net of tax | -1,098 | -3,023,000 | -69,000 | -153,000 | -919,000 | |||||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||
| net unrealized gain on marketable securities, net of tax | 17,000 | -3,509,000 | 8,188,000 | -1,363,000 | -1,939,000 | 1,294,000 | 790,000 | 1,076,000 | 4,369,000 | -2,338,500 | 421,000 | -6,752,000 | -136,000 | 13,000 | -256,000 | -540,000 | -284,000 | 485,000 | -212,000 | -317,000 | 767,000 | 77,000 | -206,000 | |||||||
| collaboration revenue: | ||||||||||||||||||||||||||||||
| collaboration revenue from customers | 1,267,000 | 294,123,000 | 35,141,000 | 10,260,000 | 184,000 | 52,480,000 | 42,141,000 | 12,514,000 | 5,285,000 | 22,936,000 | 7,922,000 | 316,810,000 | 9,388,000 | 5,811,000 | 3,552,000 | |||||||||||||||
| total collaboration revenue | 1,267,000 | 294,123,000 | 35,141,000 | 10,283,000 | 3,559,000 | 52,480,000 | 42,141,000 | 12,514,000 | 5,285,000 | 22,939,000 | 7,923,000 | 316,815,000 | 9,393,000 | 5,847,000 | 3,604,000 | |||||||||||||||
| yoy | -64.40% | 460.45% | -16.61% | -17.83% | -32.66% | 128.78% | 431.88% | -96.05% | -43.73% | 292.32% | 119.84% | |||||||||||||||||||
| qoq | -99.57% | 736.98% | 241.74% | 188.93% | -93.22% | 24.53% | 236.75% | 136.78% | -76.96% | 189.52% | -97.50% | 3272.88% | 60.65% | 62.24% | ||||||||||||||||
| comprehensive income | -100,389,000 | 184,459,000 | ||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | ||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding, basic | 168,831,329 | 137,047,227 | ||||||||||||||||||||||||||||
| weighted-average number of shares outstanding, diluted | 168,831,329 | 140,930,625 | ||||||||||||||||||||||||||||
| other collaboration revenue | 23,000 | 3,375,000 | 3,000 | 1,000 | 5,000 | 5,000 | 36,000 | 52,000 | ||||||||||||||||||||||
| income before income taxes | -119,443,000 | -99,353,000 | 183,383,000 | -98,684,000 | -103,299,000 | -58,767,000 | -75,836,000 | -84,588,000 | -60,691,000 | -70,041,000 | 245,708,000 | -58,172,000 | -58,679,000 | -56,898,000 | -53,950,000 | -46,373,000 | -58,650,000 | |||||||||||||
| income tax expense | -6,750 | -27,000 | ||||||||||||||||||||||||||||
| income tax benefit | -56,000 | -79,000 | 135,000 | -75,000 | 113,000 | 313,000 | ||||||||||||||||||||||||
| collaboration revenue | 4,672,000 | 13,604,000 | 4,197,000 | 4,205,000 | 125,676,000 | 1,195,000 | 1,648,000 | 641,000 | ||||||||||||||||||||||
| net unrealized income on marketable securities, net of tax | 547,000 | 981,000 | ||||||||||||||||||||||||||||
| interest income | 2,070,000 |
We provide you with 20 years income statements for Denali Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Denali Therapeutics stock. Explore the full financial landscape of Denali Therapeutics stock with our expertly curated income statements.
The information provided in this report about Denali Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.